Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
30 November 2024 - 8:44AM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for autoimmune diseases and cancer, today announced it
granted an inducement award on November 29, 2024.
One individual was hired by Adicet in November 2024 and granted
new hire non-qualified stock options to purchase 6,000 shares of
Adicet’s common stock with an exercise price of $1.13 per share,
the closing price of Adicet’s common stock as reported by Nasdaq on
November 29, 2024. One-fourth of the shares underlying the
employee’s option will vest on the one-year anniversary of the
recipient’s start date and thereafter the remaining three-fourths
of the shares underlying the employee’s option will vest in
thirty-six substantially equal monthly installments, such that the
shares underlying the option granted to the employee will be fully
vested on the fourth anniversary of the recipient’s start date,
subject to the employee’s continued employment with Adicet on such
vesting dates.
The above-described award was granted outside of Adicet’s
stockholder-approved equity incentive plans pursuant to Adicet’s
2022 Inducement Plan (the Inducement Plan), which was adopted by
the board of directors in January 2022 and subsequently amended in
January 2023. The award was authorized by the compensation
committee of the board of directors, which is comprised solely of
independent directors, as a material inducement to the employee
entering into employment with Adicet in accordance with Nasdaq
Listing Rule 5635(c)(4).
About Adicet Bio, Inc.
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients. For more information, please visit our website at
https://www.adicetbio.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241129244517/en/
Adicet Bio, Inc. Investor and Media Contacts
Investors: Anne Bowdidge
abowdidge@adicetbio.com
Janhavi Mohite Precision AQ 212-362-1200
janhavi.mohite@precisionaq.com
Media: Kerry Beth Daly kbdaly@adicetbio.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Nov 2024 to Dec 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Dec 2023 to Dec 2024
